潘妥拉唑

用途

• Gastric acid suppression
• All uses (ulcers, oesophagitis, hypersecretory conditions)
• Gastric acid suppression in neonatal foals
• Intravenous treatment of stress-related mucosal disease
• Gastric acid suppression
• All uses (ulcers, oesophagitis, hypersecretory conditions)

給藥方式

可能的副作用

• Diarrhea
• Headache (reported in humans)
• Hyperglycemia (rare, ~1% in humans)
• Injection site reactions (thrombophlebitis, abscess) with IV use
• Potential increased risk of community-acquired pneumonia (noted in human literature)
• Diarrhoea
• Headache
• Hyperglycaemia (rare)
• Increased risk of pneumonia
• Thrombophlebitis (associated with IV injection)

注意事項與禁忌

• Known hypersensitivity to pantoprazole or other substituted benzimidazole PPIs
• Intramuscular (IM) or Subcutaneous (SQ) administration (parenteral form must be given IV)
• Intramuscular (IM) administration
• Subcutaneous (SC) administration
• Parenteral pantoprazole MUST be administered IV; do not give IM or SQ. Reconstituted injection (4 mg/mL) must be administered intravenously over not less than 2 minutes. Use with caution in pregnant animals (FDA Category B in humans) though animal studies have not demonstrated teratogenic effects. May cause false-positive results for urine screening tests for THC.

藥物相互作用

• Ketoconazole, itraconazole, iron, ampicillin esters: Decreased drug absorption due to increased gastric pH (these drugs require an acidic environment for optimal absorption)
• Sucralfate: May decrease the bioavailability of orally administered pantoprazole
• Warfarin: Pantoprazole may increase the anticoagulant effect
• Itraconazole: Decreased absorption of itraconazole due to increased gastric pH
• Ketoconazole: Decreased absorption of ketoconazole due to increased gastric pH

常見問題